Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and ...
John Hancock Financial Opportunities Fund offers a compelling buy opportunity, trading at a 4.09% discount to NAV. See more ...
Good morning, and thank you for joining Adecoagro S.A.'s 2025 Results Conference. Today, we are presenting a larger, further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results